OnCo
Cancers & treatments·Regimen libraryAdjuvant

FEC-100

Checked 2026-09-09

Adjuvant or neoadjuvant chemotherapy for early breast cancer, usually 3 cycles followed by 3 cycles of docetaxel (FEC-T)

Also called FEC, FEC100.

One cycle

every 21 days × 3-6 · about 9 weeks in total
178141521Fluorouracil: 500 mg/m², IntravenousFluorouracilEpirubicin: 100 mg/m², IntravenousEpirubicinCyclophosphamide: 500 mg/m², IntravenousCyclophosphamide
21-day cycle × 3-6 (about 9 weeks)Intravenous

Components

DrugDoseRouteDays
Fluorouracil
Fluoropyrimidine antimetabolite
500 mg/m²IVD1
Epirubicin
Anthracycline (topoisomerase II inhibitor)
100 mg/m²IVD1
Cyclophosphamide
Alkylating agent (oxazaphosphorine prodrug)
500 mg/m²IVD1
Cycles
3-6
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Consider (10-20% FN risk)

Notes

  • Epirubicin cumulative dose limits apply; check LVEF.
  • Fluorouracil adds little in modern anthracycline-taxane sequences and is omitted in EC-T schedules.

Used in

HR-positive / HER2-negative breast cancerHER2-positive breast cancerTriple-negative breast cancer (TNBC)
Products
Fluorouracil (5-FU)EpirubicinCyclophosphamide

Source

French Adjuvant Study Group (FASG 05), JCO 2001: FEC 100 versus FEC 50

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Everolimus
Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy
every 28 days
Dose-dense AC → T
Node-positive or high-risk early breast cancer, adjuvant or neoadjuvant
every 14 days × 4
TC (docetaxel + cyclophosphamide)
Early breast cancer when an anthracycline is not wanted
every 21 days × 4
KEYNOTE-522 (pembrolizumab + chemotherapy, then adjuvant pembrolizumab)
Stage II-III triple-negative breast cancer
every 21 days × 4
TCHP
Stage II-III HER2-positive breast cancer, neoadjuvant
every 21 days × 6
APT (weekly paclitaxel + trastuzumab)
Stage I HER2-positive breast cancer, node-negative, tumour 3 cm or smaller
weekly × 12
THP (docetaxel + trastuzumab + pertuzumab)
HER2-positive metastatic breast cancer first line, then HP maintenance
every 21 days
Trastuzumab deruxtecan 5.4 mg/kg
HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC
every 21 days
All regimensCMF →